<?xml version="1.0" encoding="UTF-8"?>
<p id="Par115">Profiling of respiratory syncytial virus (RSV) antibody repertoires from the memory B cells of naturally infected adults [
 <xref ref-type="bibr" rid="CR238">238</xref>] or generation of neutralizing antibodies from RSV-infected infants [
 <xref ref-type="bibr" rid="CR239">239</xref>] has been undertaken as well. MEDI8897, an anti-RSV antibody developed by MedImmune, is currently being evaluated for safety and efficacy in Phase II clinical trial (NCT02878330).
</p>
